16日，A股盘中弱势震荡整理，北证50指数逆市上扬；港股盘中走势疲弱，两大股指小幅走低。 具体来看，沪指盘中弱势下探，深证成指、创业板指盘中一度翻红。截至收盘，沪指跌0.4%报3367.46点，深证成指微跌0.07%报10179.6点，创业板指跌0.19%报 2039.45点，上证50指数跌0.86%，北证50指数涨0.49%，沪深北三市合计成交11242亿元，较昨日减少逾660亿元。 场内约3000股飘红，汽车产业链股爆发，豪恩汽电20%涨停，亚太股份、路畅科技、万安科技等均涨停；医药板块走高，森萱医药20%涨停，拓新药业、哈三联等 连续两日涨停；可控核聚变概念拉升，中洲特材、常辅股份盘中创出新高；人形机器人概念再度活跃，兆丰股份、精锻科技等涨超10%；值得注意的是，多只强势 股持续受到资金追捧，如成飞集成（收获8连板，利君股份近8日斩获7个涨停板，中毅达3月以来已累计大涨超260%。而金融、酿酒等权重板块却集体回调。 港股方面，阿里巴巴、恒生银行、信义光能等跌超3%，绿茶集团上市首日跌逾12%；网易大涨约13%，地平线机器人涨超5%。 医药板块盘中发力走高，创新药、减肥药概念等表现亮眼。截至收盘，森萱医药 ...

Financial Data and Key Metrics Changes - First quarter revenue was $5.6 million, a decrease from $9.4 million in the same period in 2024, primarily due to the temporary suspension of sales in France and lower investments in sales and marketing [22][5] - Adjusted net operating loss narrowed by 48% to $5.9 million compared to the prior year, with gross margin expanding to 75% from 73% in the prior year and 45% in the previous quarter [5][22] - Cash and cash equivalents at the end of the first quarter were $20.4 million, providing a runway for achieving FDA approval and profitability [25][12] Business Line Data and Key Metrics Changes - Sales and marketing expenses decreased to $3.6 million from $6.1 million in the same period in 2024, driven by increased operating efficiency [23] - Research and development expenses were reduced to $2.6 million from $5.7 million, primarily due to cost reductions related to the IDISSIPPI trial [23] - General and administrative expenses decreased to $5.2 million from $6.4 million, with adjusted expenses at $3.8 million excluding one-time financing costs [24] Market Data and Key Metrics Changes - The company observed over 40% growth quarter over quarter and year over year in its B2B2C model pilot in clinics in Europe [7] - The company expects revenues to ramp as the year progresses with the expansion of the B2B2C model and enhanced sales team onboarding [8] Company Strategy and Development Direction - The company’s 2025 plan focuses on five pillars: a new commercial plan, gaining FDA approval for the Allurion balloon, achieving profitability for the ex-U.S. business, scaling the AI product platform, and resuming commercialization in France [6][7] - The company aims to combine its program with low doses of GLP-1s to create a new standard of care for obesity, targeting a sustained weight reduction of over 20% while maintaining muscle mass [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the efficiency of the new B2B2C model and the potential for significant shareholder value as millions of patients could be treated with the Elerion program [26][27] - The company is optimistic about completing its PMA submission to the FDA by June and is encouraged by the FDA's feedback during the pre-PMA meeting [12][39] Other Important Information - The company has resumed treating patients in France and is in the final phases of updating marketing collateral to reactivate placements [15] - The company does not expect any impact on gross margin from tariffs for the remainder of the year, as most components are manufactured in the U.S. [12][13] Q&A Session Summary Question: Trends in regional markets, especially with the new marketing strategy - Management noted that mature markets for GLP-1s are creating tailwinds, with patients seeking alternatives and the expansion of the direct sales force expected to drive revenue growth [29][30] Question: Timeline and patient enrollment for the GLP-1 trial - Enrollment is expected to begin in the latter half of this year, with a one-year follow-up and a target of at least 75 subjects across multiple sites in Europe [31][32] Question: Design of the trial arms - The trial will focus on validating previous retrospective work with a single arm prospective trial design, leveraging historical data for comparison [33][34] Question: Future gross margin expectations - Management expects margins to remain in the same range as the first quarter, with potential increases as revenues ramp up [35][36] Question: Details on the pre-PMA meeting and next steps - The FDA was receptive to alternative analyses for the control group data, which could strengthen the overall application [39][40] Question: Current adoption of the Elerion program and GLP-1s - There is organic adoption of the combination therapy in the field, with physicians integrating GLP-1s with the Allurion balloon [45][46] Question: Revenue performance cadence for 2025 - Management anticipates steady revenue increases driven by the onboarding of new sales team members and recovery in France [49][50] Question: Expected costs for the prospective study - The prospective trial is not expected to have a material impact on the budget, as existing patient flow and lower costs overseas will be leveraged [51][52] Question: Regulatory strategy regarding expanded labeling - The focus is on the commercial implications of the study, with potential long-term benefits for discussions with regulators and payers [53][54] Question: Procedure growth trends - Procedure volume is stable, with some growth in certain territories, and management expects a recovery in France in the second half of the year [57][58]

《野兽日报》称，特朗普12日在讲话中谈及降低美国人用药成本的计划时，突然开始提到一名体型臃肿的朋友。"我给你们讲个故事，我的一个朋友，他是 个商人，非常非常非常顶尖的人物。你们大多数人都听说过他。非常神经质、出色商人、体重严重超标，他还使用减肥药。"特朗普说。 特朗普模仿这位朋友打电话给他说，"'我在伦敦，刚为这该死的减肥药付了钱。'"而特朗普则对这位朋友回应，"我说，'这药不管用吧。'"特朗普还继续模 仿这位朋友说，"'我刚花了88美元。而在纽约我得花1300美元。这到底怎么回事？'"《野兽日报》称，特朗普这番言论引发在场一阵笑声。 报道提到，特朗普的言论在社交媒体上引发网友猜测。许多网友认为，特朗普讲的可能是马斯克。"这10000%和埃隆有关。"一位网友在X上转发相关视频帖 文时说。↓ 【环球网报道】据美国《野兽日报》报道，美国总统特朗普当地时间12日在一场讲话中提到自己一位"体重严重超标"的商人朋友抱怨减肥药价格昂贵的故 事，尽管并未指名道姓，但其言论却在社交平台X上引发网友猜测，一些人认为，这位匿名的"出色商人"很可能正是特斯拉首席执行官埃隆·马斯克；《野兽 日报》还援引马斯克旗下人工智能公司xAI开 ...

受访专家 北京中医药大学东直门医院脑病一科主任医师 万继峰 北京大学首钢医院营养科主任、内分泌科主任医师 龚雄辉 长胖会让大脑变"傻" 《柳叶刀》子刊曾发表研究发现，内脏脂肪增加0.27千克，认知年龄可衰老0.7年；《衰老与疾病》杂志 上的研究表明，内脏和皮下脂肪含量越高，大脑萎缩越严重，痴呆风险越高。 脂肪并非十恶不赦，北京中医药大学东直门医院脑病一科主任医师万继峰强调： 很多人都知道，体内脂肪过多会诱发高血脂、肥胖或脂肪肝等疾病。其实，脂肪太多还会影响大脑。 近期我国学者发表在英国《自然·精神健康》杂志的最新研究表明，长期肥胖不仅会影响神经连接和认 知功能，还会加速大脑萎缩、退化，好像在"吃"掉大脑。 《生命时报》采访专家，解读脂肪与健康的关系，并教你如何减轻"发福"带来的伤害。 脂肪是机体重要的能量储备库，1克脂肪可提供约9千卡能量，是1克碳水化合物、蛋白质的2倍多，还负 责辅助肠道吸收多种必需维生素。 脂肪组织会分泌多种激素，参与免疫和代谢调节，维持女性生殖功能。 皮下脂肪维持着体温恒定，分布在心、肾等器官周围的适量脂肪可缓冲外部冲击等。 但是，当下国人的饮食普遍高油高盐高糖，同时久坐少动，多余能量无 ...

近两年，减肥药成了医药行业里最炙手可热的明星概念。 从诺和诺德的司美格鲁肽到礼来的替尔泊肽，一系列GLP-1类药物席卷市场，引发了公众与资本市场对 代谢类药物前所未有的关注。而除了这两位先行者，更多大药企也在持续加注：一边自研新一代药物管 线，一边通过收购切入，比如2025年3月罗氏以最高总金额53亿美金重金买下Zealand管线，押注曾被忽 视的Amylin通路。 减肥药，不再只是一个产品，而是一场全面的产业竞赛。 2024年，减肥药的市场销售额已经高达500亿美金，超过可口可乐公司的470亿美金。未来这个市场还将 有2-3倍的增长。高盛分析师Chris Shibutani团队预测，到2030年，全球减肥药物市场将达到1300亿美元 的规模。而在各大药企的布局中，诺和诺德、礼来、罗氏与辉瑞的布局中，每一家都暗藏杀手锏。 但第一代"神药"背后也并非没有问题：恶心、呕吐、肌肉流失，种种副作用正在倒逼行业寻找新的突破 口。下一代减肥药会如何进化？本期，硅谷101创始人与主理人泓君联合生物医药行业的投资人郭霆和 行业长期从业者Yushan，就从这场下一代减肥药竞赛讲起，聊聊GLP-1之后的技术探索、产业动态、专 利 ...

美国总统特朗普：与制药公司讨论了减肥药事宜。美国减肥药价格高昂。 ...

美股减肥药概念股盘前加速下挫，礼来(LLY.N)、诺和诺德(NVO.N)跌幅扩大至逾5%。白宫官员称预计 糖尿病及减肥药物将成为药品价格降低的关注重点。 ...

智通财经5月12日电，美股减肥药概念股盘前加速下挫，礼来、诺和诺德跌幅扩大至逾5%。白宫官员称 预计糖尿病及减肥药物将成为药品价格降低的关注重点。 ...

白宫官员：预计糖尿病及减肥药物将成为关注重点。 ...

⑥ 【礼来资助实验表明，替尔泊肽在实验中优于司美格鲁肽】当地时间5月11日，《新英格兰医学杂 志》刊登了一项由礼来资助的减肥药研究。临床试验中，服用礼来减肥药替尔帕肽的参与者在72周内平 均减重22.8公斤，而服用诺和诺德减肥药司美格鲁肽的参与者则减重约15公斤。截至发稿，礼来下跌 2.78%。 ⑦ 【美元指数拉升，离岸人民币大涨400点】美元指数短线拉升约50点，现报101.16。美元/日元上涨 1.6%，至147.76，创4月以来最高水平。欧元/美元跌1.03%至1.114，为4月10日以来最低水平。美元/瑞 郎涨1.23%至0.842，为一个月高点。离岸人民币一度涨超400点，报7.2079。 每经记者｜岳楚鹏 每经编辑｜高涵 ① 【商务部：中美各取消了共计91%的加征关税，暂停实施24%的反制关税】5月12日，商务部新闻发 言人就中美日内瓦经贸会谈联合声明发表谈话。其中指出，美方承诺取消根据2025年4月8日第14259号 行政令和2025年4月9日第14266号行政令对中国商品加征的共计91%的关税，修改2025年4月2日第14257 号行政令对中国商品加征的34%的对等关税，其中24%的关税暂停加 ...